

1 CLAIMS

2 What is claimed is:

3
4 Claim 1. A method of extending survival and/or delaying disease progression by
5 treating a human tumor in a mammal, wherein said tumor expresses an antigen which
6 specifically binds to a monoclonal antibody or antigen binding fragment thereof which has
7 the identifying characteristics of a monoclonal antibody encoded by a clone deposited with
8 the ATCC as accession number PTA-5691 comprising administering to said mammal said
9 monoclonal antibody in an amount effective to reduce said mammal's tumor burden,
10 whereby disease progression is delayed and/or survival is extended.

11
12 Claim 2. The method of claim 1 wherein said antibody is conjugated to a cytotoxic
13 moiety.

14
15 Claim 3. The method of claim 2 wherein said cytotoxic moiety is a radioactive
16 isotope.

17
18 Claim 4. The method of claim 1 wherein said antibody activates complement.

19
20 Claim 5. The method of claim 1 wherein said antibody mediates antibody
21 dependent cellular cytotoxicity.

22
23 Claim 6. The method of claim 1 wherein said antibody is a murine antibody.

1 Claim 7. The method of claim 1 wherein said antibody is a humanized antibody.

2

3 Claim 8. The method of claim 1 wherein said antibody is a chimerized antibody.

4

5 Claim 9. An isolated monoclonal antibody encoded by the clone deposited
6 with the ATCC as PTA-5691.

7

8 Claim 10. The antibody of claim 9, which is a humanized antibody.

9

10 Claim 11. The antibody of claim 9, which is a chimerized antibody.

11

12 Claim 12. Antigen binding fragments of the isolated monoclonal antibody of
13 claim 9.

14

15 Claim 13. Antigen binding fragments of the humanized antibody of claim 10.

16

17 Claim 14. Antigen binding fragments of the chimerized antibody of claim 11.

18

19 Claim 15. The isolated antibody or antigen binding fragments of any one of
20 claims 9,10,11,12,13 or14 conjugated with a member selected from the group consisting of

1 cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells;

2 whereby antibody conjugates are formed.

3

4 Claim 16. The isolated clone deposited with the ATCC as PTA-5691.

5

6 Claim 17. A binding assay to determine presence of cancerous cells in a tissue

7 sample selected from a human tumor comprising:

8 providing a tissue sample from said human tumor;

9 providing an isolated monoclonal antibody encoded by the clone deposited with the

10 ATCC as PTA-5691, or an antigen binding fragment thereof, or an antibody conjugate

11 thereof;

12 contacting said isolated monoclonal antibody or antigen binding fragment thereof

13 or antibody conjugate thereof with said tissue sample; and

14 determining binding of said isolated monoclonal antibody or antigen binding

15 fragment thereof or antibody conjugate thereof with said tissue sample;

16 whereby the presence of said cancerous cells in said tissue sample is indicated.

17

18 Claim 18. The binding assay of claim 17 wherein the human tumor tissue

19 sample is obtained from a tumor originating in a tissue selected from the group consisting

20 of ovarian and breast tissue.

1

2 Claim 19. A process of isolating or screening for cancerous cells in a tissue
3 sample selected from a human tumor comprising:

4 providing a tissue sample from said human tumor;

5 providing an isolated monoclonal antibody encoded by the clone deposited with the
6 ATCC as PTA-5691, or an antigen binding fragment thereof, or an antibody conjugate
7 thereof;

8 contacting said isolated monoclonal antibody or antigen binding fragment thereof
9 or antibody conjugate thereof with said tissue sample; and

10 determining binding of said isolated monoclonal antibody or antigen binding
11 fragment thereof or antibody conjugate thereof with said tissue sample;

12 whereby said cancerous cells are isolated by said binding and their presence in said
13 tissue sample is confirmed.

14

15 Claim 20. The process of claim 19 wherein the human tumor tissue sample is
16 obtained from a tumor originating in a tissue selected from the group consisting of ovarian
17 and breast tissue.

18

19 Claim 21. An isolated monoclonal antibody encoded by the clone deposited
20 with the ATCC as Accession Number PTA-5690.

21

1 Claim 22. The antibody of claim 21, which is a humanized antibody.

2

3 Claim 23. The antibody of claim 21, which is a chimerized antibody.

4

5 Claim 24. Antigen binding fragments of the isolated monoclonal antibody of
6 claim 21.

7

8 Claim 25. Antigen binding fragments of the humanized antibody of claim 22.

9

10 Claim 26. Antigen binding fragments of the chimerized antibody of claim 23.

11

12

13 Claim 27. The isolated antibody or antigen binding fragments of any one of
14 claims 21,22,23,24,25 or 26 conjugated with a member selected from the group consisting
15 of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells;

16 whereby antibody conjugates are formed.

17

18

19 Claim 28. The isolated clone deposited with the ATCC as Accession Number
20 PTA-5690.

1

2 Claim 29. A binding assay to determine presence of cancerous cells in a tissue
3 sample selected from a human tumor comprising:

4 providing a tissue sample from said human tumor;

5 providing an isolated monoclonal antibody encoded by the clone deposited with the
6 ATCC as Accession Number PTA-5690 or antigen binding fragment thereof; or an antibody
7 conjugate thereof;

8 contacting said isolated monoclonal antibody or antigen binding fragment thereof or
9 antibody conjugate thereof with said tissue sample; and

10 determining binding of said isolated monoclonal antibody or antigen binding fragment
11 thereof or antibody conjugate thereof with said tissue sample;

12 whereby the presence of said cancerous cells in said tissue sample is indicated.

13

14 Claim 30. The binding assay of claim 29 wherein the human tumor tissue sample
15 is obtained from a tumor originating in a tissue selected from the group consisting of colon
16 tissue.

17

18 Claim 31. A process of isolating or screening for cancerous cells in a tissue sample
19 selected from a human tumor comprising:

20 providing a tissue sample from a said human tumor;

1 providing an isolated monoclonal antibody encoded by the clone deposited with the
2 ATCC as Accession Number PTA-5690 or antigen binding fragment thereof; or an antibody
3 conjugate thereof;
4 contacting said isolated monoclonal antibody or antigen binding fragment thereof or
5 antibody conjugate thereof with said tissue sample; and
6 determining binding of said isolated monoclonal antibody or antigen binding fragment
7 thereof or antibody conjugate thereof with said tissue sample;
8 whereby said cancerous cells are isolated by said binding and their presence in said
9 tissue sample is confirmed.

10

11 Claim 32. The process of claim 31 wherein the human tumor tissue sample is
12 obtained from a tumor originating in a tissue selected from the group consisting of colon
13 tissue.

14

15

16

17

18

19

20